Combining immunogenic cell death and cuproptosis to construct a prognostic signature and predict the immune status and treatment efficacy for hepatocellular carcinoma DOI Creative Commons
Xin Feng, M Kellis, Xin Zhang

и другие.

Holistic Integrative Oncology, Год журнала: 2024, Номер 3(1)

Опубликована: Дек. 26, 2024

Abstract Background Immunogenic cell death (ICD) is defined as sufficient to activate an adaptive immune response in immunocompetent host. Cuproptosis induced by increased intracellular toxicity due copper ion accumulation. ICD and cuproptosis have great potential regulating the growth proliferation of cancer cells. Methods We used transcriptome data from TCGA database identify two subtypes based on consensus clustering explored differences between groups. further combined ICD- cuproptosis-related genes develop a signature predict OS, status, treatment responses HCC patients. An ICGC cohort was for external validation. Results Patients groups with high expression had higher levels infiltration better immunotherapeutic response. Eight related (BAX, HSP90AA1, IFNB1, LY96, NT5E, LIPT1, DLAT, CDKN2A) were screened prognostic signature. The survival analysis revealed that patients low-risk group less likely die at early stage than those high-risk group. also showed results predicting Conclusions Our study constructed combining performs well closely associated immunotherapy.

Язык: Английский

Combining immunogenic cell death and cuproptosis to construct a prognostic signature and predict the immune status and treatment efficacy for hepatocellular carcinoma DOI Creative Commons
Xin Feng, M Kellis, Xin Zhang

и другие.

Holistic Integrative Oncology, Год журнала: 2024, Номер 3(1)

Опубликована: Дек. 26, 2024

Abstract Background Immunogenic cell death (ICD) is defined as sufficient to activate an adaptive immune response in immunocompetent host. Cuproptosis induced by increased intracellular toxicity due copper ion accumulation. ICD and cuproptosis have great potential regulating the growth proliferation of cancer cells. Methods We used transcriptome data from TCGA database identify two subtypes based on consensus clustering explored differences between groups. further combined ICD- cuproptosis-related genes develop a signature predict OS, status, treatment responses HCC patients. An ICGC cohort was for external validation. Results Patients groups with high expression had higher levels infiltration better immunotherapeutic response. Eight related (BAX, HSP90AA1, IFNB1, LY96, NT5E, LIPT1, DLAT, CDKN2A) were screened prognostic signature. The survival analysis revealed that patients low-risk group less likely die at early stage than those high-risk group. also showed results predicting Conclusions Our study constructed combining performs well closely associated immunotherapy.

Язык: Английский

Процитировано

0